Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Billaud

Showing results (61-70 of 94) with videos related to

Pageof 10
Sort By:
The EMBO Journal|August 2, 2000
The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung diseaseM C Bordeaux, C Forcet, L Granger, et al.
The Journal of Clinical Investigation|April 29, 1998
Various mechanisms cause RET-mediated signaling defects in Hirschsprung's diseaseA Pelet, O Geneste, P Edery, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 1, 1997
Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutationF M Michiels, S Chappuis, B Caillou, et al.
Current Topics in Microbiology and Immunology|January 1, 1990
Epstein-Barr virus terminal protein gene transcription is dependent on EBNA2 expression and provides evidence for viral integration into the host genomeU Zimber-Strobl, K Suentzenich, M Falk, et al.
Therapie|June 21, 2022
Pulmonary toxicity of mTOR inhibitors. Comparisons of two populations: Solid organ recipients and cancer patientsSébastien Gendarme, Jean Pastré, Eliane M Billaud, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 28, 2019
Belatacept-based immunosuppression: A calcineurin inhibitor-sparing regimen in heart transplant recipientsManon Launay, Joelle Guitard, Richard Dorent, et al.
Journal of Virology|March 1, 1990
Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23M Cordier, A Calender, M Billaud, et al.
Cancer Research|February 1, 1997
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotypeF Carlomagno, G Salvatore, A M Cirafici, et al.
Oncogene|January 8, 1999
Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteinesS Chappuis-Flament, A Pasini, G De Vita, et al.
Oncogene|July 24, 1997
Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domainA Pasini, O Geneste, P Legrand, et al.
Pageof 10

Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
The EMBO Journal|August 2, 2000
The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung diseaseM C Bordeaux, C Forcet, L Granger, et al.
The Journal of Clinical Investigation|April 29, 1998
Various mechanisms cause RET-mediated signaling defects in Hirschsprung's diseaseA Pelet, O Geneste, P Edery, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 1, 1997
Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutationF M Michiels, S Chappuis, B Caillou, et al.
Current Topics in Microbiology and Immunology|January 1, 1990
Epstein-Barr virus terminal protein gene transcription is dependent on EBNA2 expression and provides evidence for viral integration into the host genomeU Zimber-Strobl, K Suentzenich, M Falk, et al.
Therapie|June 21, 2022
Pulmonary toxicity of mTOR inhibitors. Comparisons of two populations: Solid organ recipients and cancer patientsSébastien Gendarme, Jean Pastré, Eliane M Billaud, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 28, 2019
Belatacept-based immunosuppression: A calcineurin inhibitor-sparing regimen in heart transplant recipientsManon Launay, Joelle Guitard, Richard Dorent, et al.
Journal of Virology|March 1, 1990
Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23M Cordier, A Calender, M Billaud, et al.
Cancer Research|February 1, 1997
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotypeF Carlomagno, G Salvatore, A M Cirafici, et al.
Oncogene|January 8, 1999
Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteinesS Chappuis-Flament, A Pasini, G De Vita, et al.
Oncogene|July 24, 1997
Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domainA Pasini, O Geneste, P Legrand, et al.
Pageof 10